0.375
0.02 (4.17%)
| Penutupan Terdahulu | 0.360 |
| Buka | 0.360 |
| Jumlah Dagangan | 33,814 |
| Purata Dagangan (3B) | 188,503 |
| Modal Pasaran | 61,320,372 |
| Harga / Jualan (P/S) | 65.56 |
| Harga / Buku (P/B) | 13.65 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 28 Jul 2025 - 1 Aug 2025 |
| Margin Keuntungan | -203.39% |
| Margin Operasi (TTM) | -548.94% |
| EPS Cair (TTM) | -0.060 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 35.50% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 4.69% |
| Nisbah Semasa (MRQ) | 4.70 |
| Aliran Tunai Operasi (OCF TTM) | -5.46 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -2.92 M |
| Pulangan Atas Aset (ROA TTM) | -66.25% |
| Pulangan Atas Ekuiti (ROE TTM) | -136.44% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (AU) | Bercampur | Bercampur |
| Biotechnology (Global) | Menurun | Menurun | |
| Stok | PROTEOMICS FPO [PIQ] | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 2.0 |
| Purata | 0.88 |
|
Proteomics International Laboratories Ltd is a biological research and drug discovery company. The company specializes in the area of proteomics which is the industrial-scale study of the structure and function of proteins. Its operations are divided into PromarkerD which targets the diabetes epidemic and is a predictive diagnostic test for diabetic kidney disease, a progressive disorder found in one in three adults with diabetes; its proprietary biomarker discovery platform called Promarker, which searches for protein fingerprints in a sample; and Analytical Services that are specialist contract research focusing on biosimilars quality control and pharmacokinetic testing for clinical trials. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 24.03% |
| % Dimiliki oleh Institusi | 5.59% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |